Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3

Patent metadata

Field	Value
Publication number	US-11267847-B2
Application number	US-201916415676-A
Country	US
Kind code	B2
Filing date	May 17, 2019
Priority date	Mar 4, 2009
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The present invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.

First claim

What is claimed is:

1. A nucleic acid encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO:4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22, or encoding a polypeptide comprising a functionally active variant of any of these amino acid sequences, wherein the functionally active variant:
(i) has an amino acid sequence that is at least 60% identical to any of the amino acid sequences of SEQ ID NO: 1 to 22;
(ii) is encoded by a cDNA that hybridizes in 6×SSC, 5×Denhardt's solution, 0.5% SDS at 40° C. for 2 to 12 hours to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, and SEQ ID NO: 44, or to a nucleic acid sequence complementary to any of the nucleic acid sequences of SEQ ID NO: 23 to 44; and/or
(iii) is encoded by a part of a parvoviral genome comprising an open reading frame (ORF) not in frame with that encoding VP1, VP2 and VP3, that includes more than 378 nucleotides of the VP3 ORF,
wherein the nucleic acid is incapable of expressing Rep40, Rep52, Rep68, Rep78, VP1, VP2 or VP3, and wherein the nucleic acid is comprised in an expression cassette, expression construct, expression vector, or transfected cell line.

2. The nucleic acid of claim 1 , characterized in that it encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or the amino acid sequence of SEQ ID NO: 5.

3. The nucleic acid of claim 1 , wherein the functionally active variant has an amino acid sequence that is at least 90% identical to any of the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22.

4. The nucleic acid of claim 1 , wherein the functionally active variant is encoded by a cDNA that hybridizes in 6×SSC, 5×Denhardt's solution, 0.5% SDS at 68° C. to a nucleic acid sequence complementary to any of the nucleic acid sequences of SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, and SEQ ID NO: 44.

5. The nucleic acid of claim 1 , wherein the functionally active variant is encoded by a cDNA that hybridizes in 6×SSC, 5×Denhardt's solution, 0.5% SDS to the nucleic acid sequence of SEQ ID NO: 23, or a nucleic acid sequence complementary to the nucleic acid sequence of SEQ ID NO: 23.

6. The nucleic acid of claim 1 , characterized in that it includes more than 378 nucleotides of the VP3 ORF.

7. The nucleic acid of claim 1 , characterized in that it includes at least 5 nucleotides of the adjacent VP2-encoding nucleotides, which are located directly upstream of the 5′ of the VP3 start codon, or characterized in that its start codon is an ATG at least 4 nucleotides downstream of the VP3 start codon.

8. The nucleic acid of claim 1 , characterized in that it is capable of expressing a protein promoting capsid assembly of VP3.

9. The nucleic acid of claim 1 , characterized in that it is derived from AAV2 and its translation start codon is C 2729 TG, A 2735 CG, A 2717 TT or T 2720 TG or that it is derived from another parvovirus and its translation start codon is at the homologous site to the translation start codons of AAV2.

10. The nucleic acid of claim 1 , comprising a mutation generating an ATG start codon allowing for improved translation of the open reading frame.

11. The nucleic acid of claim 1 , characterized in that the polypeptide coding sequence of the nucleic acid is followed by a poly(A) signal.

12. The nucleic acid of claim 1 , characterized in that the nucleic acid comprises a promoter driving transcription of the polypeptide-encoding sequence.

13. The nucleic acid of claim 1 , characterized in that it is derived from an adeno-associated virus (AAV), Goose parvovirus, Duck parvovirus, or Snake parvovirus.

14. The nucleic acid of claim 13 , characterized in that the AAV is selected from the group consisting of bovine AAV (b-AAV), canine AAV (CAAV), mouse AAV1, caprine AAV, rat AAV, avian AAV (AAAV), AAV1, AAV2, AAV3b, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, and AAV13.

15. The nucleic acid of claim 6 , characterized in that it includes at least 445 nucleotides of the VP3 ORF.

16. The nucleic acid of claim 7 , characterized in that it includes at least 44 nucleotides of the adjacent VP2-encoding nucleotides, which are located directly upstream of the 5′ of the VP3 start codon, or characterized in that its start codon is an ATG at 44 nucleotides downstream of the VP3 start codon.

17. The nucleic acid of claim 10 , wherein one of the translation start codons of AAV2 or the homologous sites of other parvoviruses is mutated into an ATG start codon.

18. The nucleic acid of claim 12 , wherein the nucleic acid comprises a heterologous promoter.

19. The nucleic acid of claim 14 , characterized in that the AAV is AAV2.

20. The nucleic acid of claim 1 , wherein the transfected cell line is a transfected producer cell line.

Assignees

• Deutsches Krebsforsch
• Medigene Ag

Inventors

• Sonntag Florian
• Kleinschmidt Juergen
• Hoerer Markus
• Pino Tossi Kerstin

Classifications

• C07K14/005 Primary

  from viruses · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61K2039/5256

  expressing foreign proteins · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title